CELLECTIS: directors' dealings · France · AMF

About CELLECTIS

Cellectis is a clinical-stage biotechnology company focused on gene editing and the development of innovative immunotherapies against cancer. Founded more than 25 years ago, the company built its scientific foundation around two proprietary technologies: TALEN®, its flagship gene-editing platform, and PulseAgile, its electroporation system. These technologies support the design of next-generation cell and gene therapies, with an emphasis on safety, efficacy, and manufacturing scalability. At the core of Cellectis’ business is the development of off-the-shelf allogeneic product candidates, especially gene-edited CAR-T therapies designed to be ready to use for patients. The company is primarily targeting high unmet-need hematologic cancers, including B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma. Its pipeline includes several UCART programs intended to offer a potentially more industrializable alternative to personalized autologous approaches. From a market positioning perspective, Cellectis is one of the European pioneers in applying gene editing to oncology. Its long-standing expertise in TALEN® provides a differentiated capability in precise cell engineering, which is strategically valuable in a highly competitive sector dominated by major pharmaceutical and biotechnology players. The company develops programs both internally and through scientific and industrial partnerships, including collaborations with major healthcare groups, in order to accelerate research and share development risk. Cellectis is headquartered in Paris and also maintains operations in New York and Raleigh, reflecting a transatlantic footprint that supports research, development, and investor relations. The company is listed on Euronext Growth under ALCLS and on Nasdaq under CLLS. Its latest public financial update in spring 2026 confirmed progress across multiple Phase 1 and Phase 2 clinical studies, as well as ongoing strategic collaborations, highlighting a long-term strategy centered on disruptive innovation and the value creation potential of its gene-editing platform.